Modalis Therapeutics Has Received an Orphan Drug Designation From the U.S. Food and Drug Administration for Mdl-101, a Treatment for Congenital Muscular Dystrophy Type 1a (Lama2-Cmd).
Modalis Therapeutics已經獲得了美國食品藥品監督管理局針對Mdl-101的孤兒藥物認定，這是一種治療先天性肌萎縮症類型1a（Lama2-Cmd）的藥物。
